TRANSCODE THERAPEUTICS, INC. Earnings Per Share (Basic)
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Earnings Per Share (Basic) of -$7.17 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- TRANSCODE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$7.17.
- TRANSCODE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$21.28.
- TRANSCODE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$16.49.
- TRANSCODE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$5.82.
- TRANSCODE THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$52.59.
- TRANSCODE THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$1336.63.
- TRANSCODE THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$3419.01.
- TRANSCODE THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$1082.79.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.17 10-Q · filed 2026-08-14 | -$28.14 10-Q · filed 2026-08-14 | -$44.59 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$51.13 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2026-03-31 | -$21.28 10-Q · filed 2026-05-15 | -$37.77 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$44.40 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$49.98 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-12-31 | -$16.49 derived: net income ÷ weighted average shares · filed 2026-04-15 | -$22.80 derived: net income ÷ weighted average shares · filed 2026-04-15 | -$28.12 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$52.59 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | -$5.82 10-Q · filed 2025-11-14 | -$10.95 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$34.49 10-Q · filed 2025-11-14 | -$58.40 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-06-30 | -$5.13 10-Q · filed 2026-08-14 | -$32.45 10-Q · filed 2026-08-14 | -$65.16 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$94.46 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-03-31 | -$70.16 10-Q · filed 2026-05-15 | -$2.51 10-Q · filed 2025-05-14 | -$186.47 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$291.74 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$471.01 derived: net income ÷ weighted average shares · filed 2026-05-15 | |||
| 2024-12-31 | -$281.24 derived: net income ÷ weighted average shares · filed 2026-04-15 | -$446.47 derived: net income ÷ weighted average shares · filed 2026-04-15 | -$903.92 derived: net income ÷ weighted average shares · filed 2026-04-15 | -$1336.63 10-K · filed 2026-04-15 | -$47.14 10-K · filed 2025-04-15 | |||
| 2024-09-30 | -$146.06 10-Q · filed 2025-11-14 | -$0.16 10-Q · filed 2024-11-14 | -$638.68 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$1117.89 10-Q · filed 2025-11-14 | -$1.21 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | -$680.23 10-Q · filed 2025-08-14 | -$0.74 10-Q · filed 2024-08-14 | -$1290.94 10-Q · filed 2025-08-14 | -$1.40 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | -$21.35 10-Q · filed 2025-05-14 | -$0.65 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | -$3419.01 10-K · filed 2025-04-15 | -$103.61 10-K · filed 2024-04-01 | ||||||
| 2023-09-30 | -$48.44 10-Q · filed 2024-11-14 | -$1.68 10-Q · filed 2023-11-14 | -$273.66 10-Q · filed 2024-11-14 | -$8.46 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | -$142.38 10-Q · filed 2024-08-14 | -$3.29 10-Q · filed 2023-08-14 | -$373.15 10-Q · filed 2024-08-14 | -$8.97 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | -$259.07 10-Q · filed 2024-05-15 | -$0.33 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | -$1082.79 10-K · filed 2024-04-01 | -$1.35 10-K · filed 2023-03-31 | ||||||
| 2022-09-30 | -$6.61 10-Q · filed 2023-11-14 | -$0.33 10-Q · filed 2022-11-14 | -$19.16 10-Q · filed 2023-11-14 | -$0.96 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | -$7.20 10-Q · filed 2023-08-14 | -$0.36 10-Q · filed 2022-08-15 | -$12.55 10-Q · filed 2023-08-14 | -$0.63 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | -$0.27 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | -$0.81 10-K · filed 2023-03-31 | |||||||
| 2021-09-30 | -$0.20 10-Q · filed 2022-11-14 | -$0.58 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $0.60 10-Q · filed 2022-08-15 | -$0.37 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | -$0.97 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | -$0.51 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | -$0.30 10-Q · filed 2021-11-15 | -$0.33 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | -$0.03 10-Q · filed 2021-08-23 | -$0.04 10-Q · filed 2021-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |